Restoration of LAT activity improves CAR T cell sensitivity and persistence in response to antigen-low acute lymphoblastic leukemia

Researchers designed an adjunctive LAT-activating CAR T cell (ALA-CART) platform for the treatment of antigen-low leukemias that are refractory to clinically active CD22BBz CAR T cells. The ALA-CART cells showed improved cytotoxicity, proliferation, persistence, and efficacy in this setting. The researchers concluded that the ALA-CART platform represents a promising strategy for overcoming multiple mechanisms of CAR T-cell failure.